未登录

P

Pierre Laurin

University of Ottawa

H指数:9

被引数:456

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Fatty acid mimetic PBI-4547 restores metabolic homeostasis via GPR84 in mice with non-alcoholic fatty liver disease

SCIENTIFIC REPORTS

IF3.9

2020-07-2923

OAAI

Simard, Jean-Christophe; Thibodeau, Jean-Francois; Leduc, Martin; Tremblay, Mikael; Laverdure, Alexandre; Sarra-Bournet, Francois; Gagnon, William; Ouboudinar, Jugurtha; Gervais, Liette; Felton, Alexandra; Letourneau, Sylvie; Geerts, Lilianne; Cloutier, Marie-Pier; Hince, Kathy; Corpuz, Ramon; Blais, Alexandra; Quintela, Vanessa Marques; Duceppe, Jean-Simon; Abbott, Shaun D.; Blais, Amelie; Zacharie, Boulos; Laurin, Pierre; Laplante, Steven R.; Kennedy, Christopher R. J.; Hebert, Richard L.; Leblond, Francois A.; Grouix, Brigitte; Gagnon, Lyne

Oral treatment with PBI-4547 promotes beta-oxidation and energy expenditure, and reverses liver damage and white adipose tissue fibrosis in high-fat diet and ob/ob mouse models of NAFLD

JOURNAL OF HEPATOLOGY

IF33

2019-04-010

PREAI

PBI-4050 inhibits hepatic stellate cell activation, restores autophagy, and reduces CCl4-induced liver fibrosis

JOURNAL OF HEPATOLOGY

IF33

2019-04-010

PREAI

PBI-4050 treatment decreases sepsis-induced liver injury in mice

JOURNAL OF HEPATOLOGY

IF33

2019-04-010

PREAI

PBI-4050 reduces pulmonary hypertension, lung fibrosis, and right ventricular dysfunction in heart failure

CARDIOVASCULAR RESEARCH

IF13.3

2019-02-0715

PREAI

Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis

EUROPEAN RESPIRATORY JOURNAL

IF21

2018-12-2178

OAAI

PBI-4050 Reduces Stellate Cell Activation and Liver Fibrosis through Modulation of Intracellular ATP Levels and the Liver Kinase B1/AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Pathway

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

IF3.8

2018-10-0129

OAAI

PBI-4547 Prevents Progression of Prediabetic Condition to Type 1 Diabetes in NOD Mice

IF7.5

2018-07-010

PRE

PBI-4547 Improves Glucose Metabolism and Insulin Resistance, and Reduces Liver Damage in a High-Fat Diet Mouse Model of Obesity and Metabolic Syndrome

IF7.5

2018-07-010

PRE

PBI-4050 Improves Metabolic Regulation and Diabetic Nephropathy through Reduction of ER Stress, Pro-Inflammatory/Fibrotic Markers, Galectin-3 Expression, and Inflammatory Cell Infiltration in ob/ob Mouse Model

IF7.5

2018-07-010

PRE

PBI-4547 Reverses Diabetes and Metabolic Syndrome through Regulation of Lipid/Glucose Metabolism, β-Oxidation and Fibrosis in Liver, and White Adipose Tissue in ob/ob Mice

IF7.5

2018-07-010

PRE

Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control

IF6.1

2018-05-1724

OAAI

PBI-4547 decreases hepatic stellate cell activation via AMPK signaling pathway, and reduces fibrosis in carbon tetrachloride (CCL4)-induced hepatic fibrosis model

JOURNAL OF HEPATOLOGY

IF33

2018-04-010

PREAI

PBI-4050, a potential anti-fibrotic drug, improves liver fibrosis in Alstrom Syndrome, an ultra-rare disease

JOURNAL OF HEPATOLOGY

IF33

2018-04-011

PREAI

PBI-4425, a novel first-in-class anti-inflammatory/anti-fibrotic compound, reduces pulmonary emphysema and cutaneous hyperplasia in tight-skin (Fbn-1) mouse

EUROPEAN RESPIRATORY JOURNAL

IF21

2017-12-060

PRE

PBI-4050 reduces expression of fibrosis biomarkers in the BioMAP SAEMyoF primary human small airway epithelial cells and lung myofibroblasts system

EUROPEAN RESPIRATORY JOURNAL

IF21

2017-12-060

PRE

PBI-4050 reduces liver damage and fibrosis in a high-fat diet mouse model of obesity and metabolic syndrome

JOURNAL OF HEPATOLOGY

IF33

2017-01-010

PREAI

PBI-4050 DECREASES HEPATIC STELLATE CELL ACTIVATION AND AMELIORATES FIBROSIS IN CARBON TETRACHLORIDE (CCL4)-INDUCED HEPATIC FIBROSIS MODEL

JOURNAL OF HEPATOLOGY

IF33

2016-01-011

PREAI

ORAL TREATMENT WITH PBI-4425 DECREASES FIBROSIS IN CARBON TETRACHLORIDE (CCL4)-INDUCED HEPATIC FIBROSIS MODEL

JOURNAL OF HEPATOLOGY

IF33

2016-01-010

PREAI

ORAL TREATMENT WITH PBI-4050, A NOVEL FIRST-IN-CLASS ANTI-FIBROTIC COMPOUND, REDUCES HEPATIC FIBROSIS AND HEPATOCELLULAR CARCINOMA

JOURNAL OF HEPATOLOGY

IF33

2014-04-011

PREAI